Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6418231 | 0.87 | CHRM5 (0.59) | SLC6A3SLC6A2SLC6A4CHRM2CHRM4 | |
| SCHEMBL8252572 | 0.86 | ALOX15 (0.45) | SLC6A3SLC6A2CHRM2CHRM4CHRM5 | |
| SCHEMBL8261717 | 0.86 | CHRM2 (0.51) | SLC6A3SLC6A2SLC6A4CHRM2CHRM4 | |
| SCHEMBL8254327 | 0.85 | CHRM2 (0.41) | SLC6A3SLC6A2CHRM2CHRM4CHRM5 | |
| SCHEMBL3194232 | 0.84 | SLC6A3 (0.57) | SLC6A3SLC6A2SLC6A4NR1H2ESR2 | |
| SCHEMBL8253723 | 0.84 | ESR2 (0.52) | SLC6A3SLC6A2SLC6A4CHRM2CHRM4 | |
| SCHEMBL8250997 | 0.84 | NR1H2 (0.43) | SLC6A3SLC6A2CHRM2CHRM4CHRM5 | |
| SCHEMBL8264380 | 0.83 | ESR2 (0.49) | SLC6A3SLC6A2SLC6A4CHRM2CHRM4 | |
| SCHEMBL1750511 | 0.83 | ESR2 (0.53) | SLC6A3SLC6A2SLC6A4CHRM2CHRM4 | |
| SCHEMBL7052243 | 0.83 | SLC6A3 (0.58) | SLC6A3SLC6A2SLC6A4CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137566-A1 | Substituted Piperdines as Renin Inhibitors | EHARA TAKERU | 2009-05-28 | — | — | US | disclosed |
| US-20090137566-A1 | Substituted Piperdines as Renin Inhibitors | EHARA TAKERU | 2009-05-28 | — | — | US | disclosed |
| WO-2006125621-A1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137566-A1 | Substituted Piperdines as Renin Inhibitors | REN, ACE, AGTR1 | SLC6A3 230/4885SLC6A2 281/4885SLC6A4 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.